



Universiteit  
Leiden  
The Netherlands

## A question based approach to drug development

Visser, S.J. de

### Citation

Visser, S. J. de. (2003, September 10). *A question based approach to drug development*. Retrieved from <https://hdl.handle.net/1887/28222>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/28222>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/28222> holds various files of this Leiden University dissertation

**Author:** Visser. Samuel Jacob de

**Title:** A question based approach to drug development

**Issue Date:** 2003-09-10

## A QUESTION BASED APPROACH TO DRUG DEVELOPMENT

VOOR MIJN OUDERS

**PROEFSCHRIFT** ter verkrijging van de graad van Doctor aan de Universiteit Leiden,

# A question based

op gezag van de Rector Magnificus Dr.D.D.Breimer, hoogleraar in de faculteit der Wiskunde

# approach to drug

en Natuurwetenschappen en die der Geneeskunde, volgens besluit van het College voor

# development

Promoties te verdedigen op woensdag 10 september 2003 te klokke 14:15 uur door

**SAMUEL JACOB DE VISSER**, geboren te Haarlem in 1975

**PROMOTIE COMMISSIE**

PROMOTOR

Prof. Dr A.F. Cohen

COPROMOTORES

Dr J.M.A. van Gerven

Dr B. Tuk, *Tuk Management B.V.*

REFERENT

Prof. Dr J. Urquhart, *Maastricht University & UCSF, San Francisco, USA*

OVERIGE LEDEN

Prof. Dr E. Uchida, *Showa University, Tokyo, Japan*

Prof. Dr M. Danhof

Prof. Dr E.C. Klasen

The printing of this thesis was financially supported by the foundation  
'Centre for Human Drug Research', Leiden, The Netherlands

Design: Caroline de Lint, Voorburg

## CONTENTS

	<b>INTRODUCTION</b>
<b>PAGE 8</b>	1. Drug development project management by a new question based approach and decision analysis support
	<b>SECTION 1</b>
<b>PAGE 30</b>	2. Biomarkers for the effects of antipsychotic drugs in healthy volunteers
<b>PAGE 56</b>	3. Biomarkers for the effects of benzodiazepines in healthy volunteer
<b>PAGE 78</b>	4. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers
<b>PAGE 96</b>	<b>THE VALUE OF RESEARCH ON BIOMARKERS</b>
	<b>SECTION 2</b>
<b>PAGE 110</b>	5. Comparison of an oral solution and an oral sustained release formulation of rilmenidine in eight healthy volunteers and correlation with in vitro sustained release properties
<b>PAGE 126</b>	6. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects
<b>PAGE 140</b>	7. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients
<b>PAGE 158</b>	8. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients
<b>PAGE 174</b>	<b>THE VALUE OF TIMING ADDITIONAL STUDIES</b>
	<b>SECTION 3</b>
<b>PAGE 182</b>	9. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy male and female volunteers. An interethnic comparative study between Japanese and Caucasian volunteers
<b>PAGE 198</b>	10. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE)
<b>PAGE 214</b>	<b>ADDED VALUE OF BRIDGING STUDIES</b>
	<b>SECTION 4</b>
<b>PAGE 224</b>	11. Pharmacodynamic and pharmacokinetic effects of MRLA023, a GABA <sub>A</sub> $\alpha_{2,3}$ subtype selective agonist, compared to lorazepam and placebo in healthy volunteers
<b>PAGE 240</b>	<b>THE VALUE OF DETERMINING CRITICAL QUESTIONS EARLY</b>
<b>PAGE 246</b>	12. Summary and Conclusions
<b>PAGE 260</b>	13. Samenvatting en Conclusies
<b>PAGE 271</b>	Curriculum Vitae